Tessa Romero
Stock Analyst at JP Morgan
(4.44)
# 357
Out of 5,182 analysts
83
Total ratings
53.12%
Success rate
22.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Maintains: Neutral | $31 → $36 | $32.92 | +9.36% | 9 | Apr 6, 2026 | |
| SEPN Septerna | Maintains: Overweight | $34 → $38 | $23.09 | +64.57% | 1 | Mar 24, 2026 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $34 → $45 | $32.82 | +37.11% | 12 | Mar 17, 2026 | |
| CYTK Cytokinetics | Maintains: Overweight | $74 → $75 | $65.01 | +15.37% | 7 | Mar 17, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $47 → $50 | $49.96 | +0.08% | 7 | Mar 16, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $31 → $34 | $21.74 | +56.39% | 12 | Mar 4, 2026 | |
| DYN Dyne Therapeutics | Maintains: Neutral | $17 → $16 | $18.68 | -14.35% | 8 | Jan 20, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $60 → $62 | $58.40 | +6.16% | 4 | Jan 9, 2026 | |
| OCS Oculis Holding AG | Initiates: Overweight | $38 | $27.30 | +39.19% | 1 | Dec 19, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $47 → $15 | $9.17 | +63.58% | 8 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $261 → $263 | $3.49 | +7,435.82% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.04 | - | 5 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $10 | $5.98 | +67.22% | 2 | May 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $10.49 | +262.25% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.33 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $29 | $14.19 | +104.37% | 3 | Aug 13, 2024 |
Agios Pharmaceuticals
Apr 6, 2026
Maintains: Neutral
Price Target: $31 → $36
Current: $32.92
Upside: +9.36%
Septerna
Mar 24, 2026
Maintains: Overweight
Price Target: $34 → $38
Current: $23.09
Upside: +64.57%
Edgewise Therapeutics
Mar 17, 2026
Maintains: Overweight
Price Target: $34 → $45
Current: $32.82
Upside: +37.11%
Cytokinetics
Mar 17, 2026
Maintains: Overweight
Price Target: $74 → $75
Current: $65.01
Upside: +15.37%
Scholar Rock Holding
Mar 16, 2026
Maintains: Overweight
Price Target: $47 → $50
Current: $49.96
Upside: +0.08%
ACADIA Pharmaceuticals
Mar 4, 2026
Maintains: Overweight
Price Target: $31 → $34
Current: $21.74
Upside: +56.39%
Dyne Therapeutics
Jan 20, 2026
Maintains: Neutral
Price Target: $17 → $16
Current: $18.68
Upside: -14.35%
Xenon Pharmaceuticals
Jan 9, 2026
Maintains: Overweight
Price Target: $60 → $62
Current: $58.40
Upside: +6.16%
Oculis Holding AG
Dec 19, 2025
Initiates: Overweight
Price Target: $38
Current: $27.30
Upside: +39.19%
Biohaven
Nov 20, 2025
Maintains: Overweight
Price Target: $47 → $15
Current: $9.17
Upside: +63.58%
Nov 18, 2025
Downgrades: Underweight
Price Target: $261 → $263
Current: $3.49
Upside: +7,435.82%
Sep 16, 2025
Downgrades: Underweight
Price Target: n/a
Current: $2.04
Upside: -
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $5.98
Upside: +67.22%
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $10.49
Upside: +262.25%
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $8.33
Upside: -
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $14.19
Upside: +104.37%